RNXT Share Price Performance
US$0.90
-0.25 (-21.74%)
78.6% undervalued intrinsic discount
US$4.20
Fair Value
Price US$0.90
Stock_Research_Today US$4.20
AnalystConsensusTarget US$5.56
Fair ValueUS$4.20
Share Pricen/a
RenovoRx, Inc. Stock Price
- 2 Narratives written by author
- 3 Comments on narratives written by author
- 240 Fair Values set on narratives written by author
RNXT Community Narratives
ST
Fair Value US$4.2 78.6% undervalued intrinsic discount
Revolutionizing Cancer Treatment
16users have liked this narrative
3users have commented on this narrative
129users have followed this narrative
AN
Fair Value US$5.56 83.8% undervalued intrinsic discount
Targeted Oncology Platform Will Drive Expanding Treatment Adoption Over The Coming Years
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Revolutionizing Cancer Treatment
A Precision Approach to Hard-to-Treat Cancers RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is a clinical-stage biopharma company taking a new approach to cancer treatment.Read more
7.5k
users have viewed this narrative16users have liked this narrative
3users have commented on this narrative
129users have followed this narrative
ST
US$4.2
78.6% undervalued intrinsic discount
Stock_Research_Today's Fair Value
Revenue
371.3% p.a.
Profit Margin
36%
Future PE
15x
Price in 2029
US$3.98
Targeted Oncology Platform Will Drive Expanding Treatment Adoption Over The Coming Years
Catalysts About RenovoRx RenovoRx is a clinical stage medical technology company developing targeted intra arterial drug delivery solutions for difficult to treat solid tumors. What are the underlying business or industry changes driving this perspective?Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$5.56
83.8% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
267.15% p.a.
Profit Margin
24.83%
Future PE
22.12x
Price in 2028
US$6.82
Trending Discussion
Recently Updated Narratives
ST
Revolutionizing Cancer Treatment
Fair Value: US$4.2 78.6% undervalued intrinsic discount
129 followersusers have followed this narrative
3 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Targeted Oncology Platform Will Drive Expanding Treatment Adoption Over The Coming Years
Fair Value: US$5.56 83.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
RenovoRx, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.30
- 67.78%
- -1,196.66%
- 0%
About RNXT
- Founded
- 2009
- Employees
- 10
- CEO
- WebsiteView website
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
